Briggs N C, Battjes R J, Cantor K P, Blattner W A, Yellin F M, Wilson S, Ritz A L, Weiss S H, Goedert J J
National Cancer Institute, National Institute on Drug Abuse, National Institutes of Health, Bethesda, Maryland, USA.
J Infect Dis. 1995 Jul;172(1):51-8. doi: 10.1093/infdis/172.1.51.
Seroprevalence of human T lymphotropic virus (HTLV) and human immunodeficiency virus type 1 (HIV-1) was determined among 7841 intravenous drug users (IVDUs) from drug treatment centers in Baltimore, Chicago, Los Angeles, New Jersey (Asbury Park and Trenton), New York City (Brooklyn and Harlem), Philadelphia, and San Antonio, Texas; 20.9% had evidence of HTLV infection, as determined using a p21e EIA for screening and p21e blot for confirmation. With a type-specific EIA and blot used in combination, HTLV-II was identified in 97.6% of HTLV-positive IVDUs whose sera could be subtyped. HIV-1 seroprevalence was 13.2%. HTLV-II without HIV-1 was most common in Los Angeles and San Antonio. HIV-1 without HTLV-II was most common in New York, New Jersey, and Baltimore. Dual infection was most common in New York and New Jersey. Logistic regression analysis revealed that seroprevalence of HTLV-II was significantly greater with HIV-1 infection and increasing age and among women, blacks, and Mexican-Americans. In conclusion, it appears that among US IVDUs, nearly all HTLV infection is attributable to HTLV-II, and HTLV-II infection is associated with HIV-1 and sociodemographic background.
在来自巴尔的摩、芝加哥、洛杉矶、新泽西（阿斯伯里帕克和特伦顿）、纽约市（布鲁克林和哈莱姆）、费城以及得克萨斯州圣安东尼奥的戒毒治疗中心的7841名静脉吸毒者中，测定了人类嗜T淋巴细胞病毒（HTLV）和1型人类免疫缺陷病毒（HIV-1）的血清流行率；使用p21e酶免疫测定法进行筛查并使用p21e印迹法进行确认，结果显示20.9%的人有HTLV感染证据。采用特异性类型的酶免疫测定法和印迹法相结合，在血清可进行亚型分型的97.6%的HTLV阳性静脉吸毒者中鉴定出了HTLV-II。HIV-1血清流行率为13.2%。无HIV-1的HTLV-II在洛杉矶和圣安东尼奥最为常见。无HTLV-II的HIV-1在纽约、新泽西和巴尔的摩最为常见。双重感染在纽约和新泽西最为常见。逻辑回归分析显示，HIV-1感染、年龄增加以及在女性、黑人及墨西哥裔美国人中，HTLV-II的血清流行率显著更高。总之，在美国静脉吸毒者中，几乎所有HTLV感染都归因于HTLV-II，且HTLV-II感染与HIV-1及社会人口统计学背景相关。
